PURPOSE OF REVIEW Atopic dermatitis is a chronic, systemic disease with primary cutaneous clinical manifestations and is commonly attributed to an exaggerated Th2 inflammatory response. Recent research regarding risk factors, prevention, clinical features, and management of atopic dermatitis will be reviewed. RECENT FINDINGS In the last decade, advances have been made in identifying the factors that either confer increased risk for or protection from atopic dermatitis and associated atopy. Progress has also been made in the clinical management of this disease. Promising biomarkers and therapeutically informative characteristics of this disease have been identified in young children with and without the presence of eczema, but much has yet to be elucidated. Progress has also been made in clarifying the advantages and disadvantages of respective medical managements, including but not limited to topical corticosteroids, topical calcineurin inhibitors, phototherapy, systemic immunosuppressants, and targeted immunotherapy. Given that medical management may show variable efficacy in a child, an optimized skin care regimen is of utmost importance as well. SUMMARY Atopic dermatitis is a challenging, chronic systemic disease that incurs significant morbidity in affected children. Although management options have been somewhat disappointing in years past, promising results have been observed in recent advances in targeted immunotherapy.

中文翻译：

---

治疗儿童特应性皮炎的实用方法。

综述目的特应性皮炎是一种慢性全身性疾病，以皮肤临床表现为主，通常归因于过度的 Th2 炎症反应。将回顾有关特应性皮炎的危险因素、预防、临床特征和治疗的最新研究。最近的发现 在过去的十年中，在确定增加特应性皮炎和相关特应性风险或预防特应性皮炎和相关特应性的风险的因素方面取得了进展。该疾病的临床治疗也取得了进展。已经在患有和不患有湿疹的幼儿中发现了这种疾病的有希望的生物标志物和治疗信息特征，但还有很多东西有待阐明。在阐明各自医疗管理的优缺点方面也取得了进展，包括但不限于局部皮质类固醇、局部钙调神经磷酸酶抑制剂、光疗、全身免疫抑制剂和靶向免疫治疗。鉴于医疗管理对儿童的疗效可能存在差异，优化的皮肤护理方案也至关重要。摘要 特应性皮炎是一种具有挑战性的慢性全身性疾病，在受影响的儿童中发病率很高。尽管过去几年的治疗方案有些令人失望，但靶向免疫治疗的最新进展已经观察到了有希望的结果。